Corient Private Wealth
AUPH icon

Corient Private Wealth’s Aurinia Pharmaceuticals AUPH Stock Holding History

Corient Private Wealth’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$358K Sell
21,106
-4,212
-17% -$67.3K ﹤0.01% 2442
2026
Q1 		$375K Sell
25,318
-2,104
-8% -$30.8K ﹤0.01% 2193
2025
Q4 		$437K Sell
27,422
-1,138
-4% -$16.1K ﹤0.01% 1935
2025
Q3 		$316K Sell
28,560
-1,000
-3% -$10.9K ﹤0.01% 2085
2025
Q2 		$250K Buy
29,560
+10,768
+57% +$86.3K ﹤0.01% 2101
2025
Q1 		$151K Sell
18,792
-1,063
-5% -$8.61K ﹤0.01% 2116
2024
Q4 		$178K Sell
19,855
-2,000
-9% -$16.3K ﹤0.01% 2147
2024
Q3 		$160K Sell
21,855
-1,250
-5% -$7.75K ﹤0.01% 2260
2024
Q2 		$132K Sell
23,105
-250
-1% -$1.32K ﹤0.01% 2183
2024
Q1 		$117K Sell
23,355
-1,100
-4% -$7.46K ﹤0.01% 2169
2023
Q4 		$220K Sell
24,455
-9,266
-27% -$76.3K ﹤0.01% 2024
2023
Q3 		$262K Buy
+33,721
New +$330K ﹤0.01% 1806

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Corient Private Wealth's AUPH Position: Q2 2026 in Review

Corient Private Wealth reduced its Aurinia Pharmaceuticals (AUPH) stake by 17% in Q2 2026, selling an estimated $67.3K and leaving 21,106 shares worth $358K. The position accounts for ﹤0.01% of the portfolio, ranked #2442.

Corient Private Wealth first reported a position in AUPH in Q3 2023 and has held it in 12 quarters since. The position peaked at $437K in Q4 2025. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Corient Private Wealth held 21,106 shares of Aurinia Pharmaceuticals worth $358K as of Q2 2026.
  • Corient Private Wealth sold 4,212 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $67.3K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2442 holding.
  • Corient Private Wealth first reported a position in Aurinia Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • Corient Private Wealth's Aurinia Pharmaceuticals position peaked at $437K in Q4 2025.
  • 282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.